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Background: Pseudomonas aeruginosa sinusitis may be the focus for intermittent lung colonization in patients with cystic ﬁbrosis (CF). The
sinusitis may induce elevated IgA levels in nasal secretion and saliva against P. aeruginosa.
Methods: 120 CF patients chronically infected, intermittently colonized or without P. aeruginosa in the lungs participated in this cross-sectional
study. IgA and IgG against P. aeruginosa sonicate and alginate were measured in nasal secretions, saliva, and in serum by ELISA.
Results: The intermittently colonized patients had signiﬁcantly higher IgA levels in nasal secretions and saliva than those without P. aeruginosa in
the lungs, indicating that P. aeruginosa sinusitis may precede intermittent colonization and chronic infection of the lungs.
Conclusions: Speciﬁc IgA against P. aeruginosa in nasal secretions and saliva can contribute to differentiation between patients chronically
infected, intermittently colonized, and without P. aeruginosa in the lungs. The diagnostic value of the IgA ELISA awaits a prospective study.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Cystic ﬁbrosis; Colonization; IgA antibodies; Diagnosis; Sinusitis1. Introduction
Patients with Cystic Fibrosis (CF) have increased susceptibil-
ity to infections, and Pseudomonas aeruginosa is the cause of
most of the morbidity and mortality in these patients [1]. Lung
infections with P. aeruginosa cause inflammation resulting in
gradually declining lung function and a systemic increase of
antibodies against a polyvalent P. aeruginosa antigen (Standard⁎ Corresponding author at: Department of Otolaryngology – Head & Neck
Surgery and Audiology, Rigshospitalet, Copenhagen. Blegdamsvej 9, 2100
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doi:10.1016/j.jcf.2012.07.001lishedAntigen (St-Ag)) [2] and the mucoid extracellular polysaccharide
alginate [3,4]. In addition to serum, specific antibodies are present
in tears and upper airways such as saliva and sputum; secretory
immunoglobulin A being the dominant antibody on mucosal
surfaces [4,5].
The immune system of the upper airways differs from that of
the lower airways, by generating an early local response with a
high plasma cell production of IgA when infected with P.
aeruginosa [6,7]. The non-phlogistic IgA, binds P. aeruginosa
on the mucosal surface, reducing the inflammatory response,
inhibiting complement activation and the recruitment of
polymorphonuclear leucocytes (PMN), and diminishing their
oxidative burst by preventing fagocytosis [6,8]. P.aeruginosaby Elsevier B.V. All rights reserved.
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reservoir, even before intermittently colonizing and chronically
infecting the lungs [9]. The reduced inflammation contributes to
this rather ‘silent’ adaptation, allowing P. aeruginosa to evolve to
the chronic biofilm phenotype in the paranasal sinuses [9,10].
When CF patients become intermittently colonized in the lungs
with P. aeruginosa, elevated levels of specific IgG against P.
aeruginosa, measured by ELISA, can be detected 1–3 years
before onset of the chronic lung infection, maybe reflecting a
‘hidden’ focus for subsequent intermittent lung colonization and
chronic infection [8]. The ‘hidden focus’ may be the paranasal
sinuses, which in CF patients frequently contain P. aeruginosa and
are filled with mucus and pus [6,10]. In fact, re-infection of
the lungs of transplanted CF patients often originates from
the paranasal sinuses [11–14]. Chronic lung infection can be
postponed by early antibiotic treatment of intermittent colonization
[15]. Serological assays (IgG) have high sensitivity and specificity
in distinguishing between CF patients chronically and not
chronically P. aeruginosa infected in the lungs [16,17]. However,
these methods have not been useful to distinguish between CF
patients with intermittent colonization and patients without
P. aeruginosa in the lungs [16–19], but the possible presence of
P. aeruginosa sinusitis as a focus for subsequent lung colonization
and chronic infection was not considered at the time of these
publications. A diagnostic antibody assay for early detection of
P. aeruginosa infection in the paranasal sinuses would therefore be
useful [20]. As secretory IgA antibodies are detectable in CF
patients with chronic P. aeruginosa lung infection [4], we
hypothesized that P. aeruginosa sinusitis may cause a local rise
in the specific IgA in nasal secretions and saliva, which could be
used to diagnose P.aeruginosa sinusitis in addition to detection
of P. aeruginosa by cultures from the sinuses. The clinical
consequence could, hopefully, be successful attempts to
eradicate P. aeruginosa from the paranasal sinuses and thereby
prevent subsequent intermittent colonization and chronic
infection of the lungs.
2. Material and methods
2.1. Patients
All CF patients above the age of seven, who were treated at the
CF centre Copenhagen, were eligible for this cross-sectional study.
The CF-diagnoses were based on characteristic clinical features,
abnormal sweat electrolytes and genotypes. The CF patients are
followed in the out-patient clinic every month, and the examina-
tions are composed of sputum samples taken for microbiological
examinations and regularly blood samples are analyzed for
anti-bacterial antibodies [8]. In total 120 CF patients (60/60 male/
female, mean age 22 years) participated in the study; saliva and
nasal secretions were obtained from 73 patients, 24 patients had
only saliva samples obtained and 23 patients had only nasal
secretions obtained. Nasal secretions and new blood samples were
obtained approximately six months later than the saliva samples.
All patients had blood samples analyzed. Patients who both had
sputum and nasal secretions obtained had two separate blood
samples analyzed.Twelve healthy employees from the Department of Clinical
Microbiology Rigshospitalet participated as healthy controls.
2.2. Infection status
As reported previously, we defined chronicP. aeruginosa lung
infection (CF+P (c)) as growth of this bacteria in six consecutive
monthly samples taken from lower respiratory tract secretions, or
a shorter period if there were two or more precipitating
antibodies against P. aeruginosa [16,19]. Lung transplanted
patients were categorized according to their infection status
before transplantation.
Intermittent lung colonization was defined as growth of P.
aeruginosa for less than 6 months, but normal levels of
precipitating antibodies (0–1) against P. aeruginosa. If the
monthly samples had never contained P. aeruginosa, patients
were classified as without P. aeruginosa.
Based on these criteria the patients were divided into four
groups: 1: CF patients without P. aeruginosa in the lungs (CF-P) 2:
intermittently colonized with P. aeruginosa (CF+P(i)) in the
lungs, 3: chronically infected in the lungs with P. aeruginosa
(CF+P(c)) or 4: colonized/infected in the lungs with other CF
pathogenic Gram-negative bacteria (Stenotrophomonas maltho-
philia, Achromobacter xylosoxidans or Burkholderia cepacia
complex)(CF+GNB).
2.3. Collection of serum, saliva, and nasal secretions
The blood samples and secretions were obtained simultaneous-
ly. Mixed saliva was collected by using four sterile 6 mm diameter
paper discs (Antibiotica Testblættchen, Struers, Copenhagen,
Denmark) which were placed on the oral mucosa for 30 s as
reported previously [5].
Nasal secretions were obtained by using four sterile 6 mm
paper discs as mentioned above (Fig. 1B). With forceps, the
discs where gently stroked against the mucosa for five seconds,
each absorbing nasal secretions. Depending on the patients'
anatomy and co-operation the anterior part of the medial
meatus could be reached, being the anatomical target for the
discs (Fig. 1B). No decongestion was used. The patients
decided if the samples were taken from the left, right or both
sides. The saliva/nasal secretion-containing paper discs were
stored at room temperature until analyzed.
2.4. IgA and IgG against P. aeruginosa
Serum and eluates of saliva and nasal secretions from the
paper discs were examined for IgA and IgG antibodies against
P. aeruginosa alginate and P. aeruginosa sonicate ((St-Ag)
(serogroups 1–17)) using enzyme-linked immunosorbent assays
(ELISA) as reported previously [4,5]. Saliva- and nasal secretion
impregnated paper-discs (mean: 25 μl/disc as reported previous-
ly [5]) were incubated on a shaker for one hour at 35 °C in 175 μl
dilution buffer to elute IgG and IgA antibodies (1:8 dilution).
Serum was diluted 1:100 for the St-Ag ELISAs and 1:4000 for
the alginate ELISAs. The volume of diluted serum samples for
the ELISA was 100 μl, and 50 μl for the saliva and nasal
Fig. 1. A–F. A: A structure we thought was an abscess, but it turned out to be a sterile sinus-associated-lymphoid-tissue with plasma cells and IgA. B: Blotting paper
within the right middle meatus absorbing nasal secretions. C: 09-33224 IgA x 40. Immunoreaction visualizing IgA immunoreactive (brown) plasma cells (arrows) in
the lamina propria close to the pseudostratified respiratory surface epithelium. D: 09-32541 IgA x 10. An accumulation of IgA containing plasma cells (brown, large
arrow) in the lamina propria close to the mucosal surface and also a strong IgA immunoreaction in the luminal mucosal layer (brown, smaller arrows). E and F:
01-586 IgA x 25 IgA immunoreactive plasma cells (brown) concentrated around secretory acini of the glands of the sinus tissue and also positive immunoreaction in
secretions in the excretory ducts (arrows).
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0.1% Tween-20 (Sigma) (washing buffer)+NaCl 15 g/l (= di-
lution buffer) was used and the plates were washed three times.2.4.1. Antibodies against alginate (IgA-alginate, IgG-alginate)
Ninety-six-well microtiter plates (Mikrowell, BiotechLine A/S,
Denmark) were coated with alginate (10 μg/ml) purified from a
mucoid CF P. aeruginosa strain (6680NH) as previously reported
[7]. The plates were coated overnight at 35 °C and blocked for one
hour at 35 °C in dilution buffer. Diluted serum, saliva and nasal
secretions (see above) were added and allowed to react for one
hour at 35 °C. After washing, horseradish peroxidase (HRP)-
conjugated rabbit anti-human IgA (P0216) and anti-human IgG(P0214) (Dako A/S, Glostrup, Denmark) both diluted 1:10,000
were added and left to react for one hour at 35 °C.
2.4.2. Antibodies against P. aeruginosa standard antigen (IgA-
St-Ag, IgG-St-Ag)
A sonicated cell extract of P. aeruginosa serogroups 1–17 was
used as standard antigen (St-Ag, protein concentration 16 mg/ml)
[4,5] and coated onto irrigated 96-well polystyrene plates
(Maxisorb, BiotechLine A/S, Denmark) at a dilution of 1:2000.
The plates were incubated for one hour at room temperature and
blocked overnight with dilution buffer at 4 °C. Serum was diluted
1:100, saliva and nasal secretion 1:8 and allowed to react for one
hour at room temperature. After washing, horseradish peroxidase
(HRP)-conjugated rabbit anti-human IgA (P0216) and anti-human
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were added and left to react for one hour at room temperature.
For all ELISAs TMBPlus was added (KemEnTecDiagnostics).
The reactions were stopped after one hour at room temperature by
adding 1 MH2SO4. The absorbance was measured at 450 nm on a
plate reader (Multiscan EX, Bie&Berntsen, Denmark). The results
were expressed as optical density values (OD).2.5. Immunohistochemistry
The presence and localization of IgA in mucus and plasma cells
in the mucosal tissue were visualized by means of immunohisto-
chemistry. Resected nasal polyps and mucosa from the maxillary
sinus from two CF+P(c) and two CF+P(i) (Fig. 1A) were fixed in
4% buffered paraformaldehyde and embedded in paraffin and
4 μm sections were cut on a microtome. The sections were
incubated for 10 min in 2% bovine serum albumine followed by
18 h at 4 °C after addition of a polyclonal rabbit anti-human IgA
(IMGENEX, IMG-80368) diluted 1:100. For visualization of the
immunoreaction the sections were incubated for 1 h with
biotinylated goat anti-rabbit immunoglobulin (BA-1000, Vector)
diluted 1:200, followed by StreptABComplex/horseradish perox-
idase (Vectastain, PK-4000), and finally visualized by means of
3,3-diaminobenzidine for 15 min. The sections were counter-
stained with hematoxylin (Fig. 1C–F).Table 1
Mean nasal and serum antibodies against P. aeruginosa (PA).
Nasal
IgA
Serum
IgA
Nasal
IgG
Serum
IgG
Nasal
IgA
Nasal
IgG
Serum
IgA
Serum
IgG
Non-CF control
group,
0.17 0.05 0.09 0.12 3.29 0.92
n=9 0.63 0.51 0.28 0.96 1.74 0.24
CF-P, n=32 0.28‡ 0.13 0.09‡ 0.12 ⁎ 2.57‡ 0.84 ⁎
(0.20) (0.08) (0.05) (0.09) (1.83) (0.40)
0.77‡ 0.73 ⁎ 0.19‡ 1.01‡ 1.99 0.19¤2.6. Sinus and nasal bacterial colonization/infection
We randomly chose 20 of our (CF-P) patients (13/7 male/
female, mean age 16 years) and cultured their nasal cavity to
determine if they were also free from P. aeruginosa (and other
CF pathogens) in the nose and sinuses. Wearing a headlight and
using a nasal speculum, the nasal cavities were examined by
one ENT surgeon (one of the authors, K.A.). In each side of the
nose a thin cotton swab was wiped within the middle meatus.
Furthermore, a nasal irrigation was performed using a plastic
Neti Pot (Yogaprosess A/S) containing 100 ml of sterile saline.
The saline was poured through one nostril, passed through the
nasal cavity and out of the other nostril where 10 ml were
collected. Finally, a sputum sample or an endolaryngeal suction
was taken [21]. This provided four different samples which
were cultured the same day.(0.28) (0.57) (0.13) (0.45) (2.28) (0.13)
CF+P(i), n=24 1.03 0.14 0.50 0.30 27.92 2.80
(0.68) (0.14) (0.50) (0.26) (83.42) (3.64)
1.33 1.21 0.64 1.68 1.99 0.38
(0.35) (0.87) (0.59) (0.64) (1.87) (0.27)
CF+P(c), n=25 1.70¤ 0.45‡ 0.63 ⁎ 0.85‡ 4.84 ⁎ 1.16
(0.60) (0.31) (0.50) (0.71) (2.79) (1.41)
1.46 1.65 ⁎ 0.96¤ 2.52‡ 1.06 ⁎ 0.38
(0.47) (0.68) (0.41) (0.77) (0.58) (0.16)
The standard deviations are shown in brackets. The ratios were first calculated
for each individual and following the mean values were calculated. The white
marked numbers refer to alginate; the grey marked numbers refer to standard
antigen.
⁎ :Pb0.05, ¤:Pb0.01 and ‡:Pb0.0001 and when the CF+P(i) are compared
with CF-P or when the CF+P(i) are compared with CF+P(c). None of the
values form the control group differed signiﬁcantly from the CF-P group.2.7. Ethics
The study was approved by the local ethics committee
(H-A-2008-141). All patients gave informed consent. In patients
b18 years a consent was also obtained from their parents.
Obtaining the saliva samples did not involve any discomfort for
the patients. Obtaining nasal secretions could result in a little
discomfort; therefore in a couple of cases fewer samples were
taken. The serum and saliva samples were part of the routine, thus
no extra blood samples were taken. The antibody results did not
result in any change of the treatment modality for the involved
patients.2.8. Statistics
SAS 9.1.3 was used for analyzing data, making receiver
operating characteristic (ROC) curves and Spearman rank
coefficient test. The St-Ag and alginate data were unpaired,
continuous and positively skewed distributed why Log10 trans-
formations weremade. The transformed data had an approximately
normal distribution justifying an unpaired two-sample t-test for the
means and a oneway analysis of variance. The level of significance
was set to ≤0.05 (two-tailed).3. Results
The results of the antibody measurements are shown in
Table 1A and B.
CF+P(c) had the highest IgA and IgG antibody levels
against St-Ag and alginate in serum, nasal secretions (Table 1)
and saliva (Table 2) compared with CF+P(i) and with CF-P (all
p-valuesb0.0001 except IgA against St-Ag which was not
significantly different between CF+P(c) and CF+P(i)).
Generally, the nasal/serum (Table 1) and the saliva/serum
(Table 2) IgA ratios were high in CF+P(c) in accordance with a
local mucosal production of IgA, in contrast to the low IgG
ratios being in accordance with a high systemic production and
subsequent transudation of IgG to the mucosa secretions.
CF+P(i) had higher IgA and IgG antibody levels against
St-Ag and alginate than CF-P (all p valuesb0.0001) (Tables 1
& 2). Nasal IgA against alginate was also higher in CF+P(i)
compared to CF-P (Fig. 2G).
Table 2
Mean sputum and serum antibodies against P. aeruginosa.
Saliva
IgA
Serum
IgA
Saliva
IgG
Serum
IgG
Saliva
IgA
Saliva
IgG
Serum
IgA
Serum
IgG
Non-CF control
group,
0.19 0.05 0.10 0.12 4.00 1.07
n=12 0.48 0.52 0.07 0.98 1.21 0.12
CF-P, n=19 0.23 0.09 0.07 0.17 2.88 ⁎ 0.58
(0.22) (0.06) (0.03) (0.17) (2.49) (0.29)
0.26 ⁎ 0.54 ⁎ 0.07 1.51 0.80 0.07
(0.21) (0.49) (0.03) (0.86) (0.75) (0.06)
CF+P(i), n=47 0.38 0.08 0.08 0.26 5.62 0.51
(0.39) (0.04) (0.06) (0.34) (5.87) (0.27)
0.45 0.92 0.07 1.68 0.77 0.05
(0.33) (0.73) (0.02) (0.72) (0.72) (0.02)
CF+P(c), n=23 0.82‡ 0.20‡ 0.21‡ 0.74‡ 5,06 0.35 ⁎
(0.48) (0.14) (0.22) (0.66) (3.99) (0.18)
0.71‡ 1.23‡ 0.25‡ 2.59 ⁎ 0.67 0.09¤
(0.33) (0.56) (0.21) (0.37) (0.44) (0.07)
The standard deviations are shown in brackets. The ratios were first calculated
for each individual and following the mean values were calculated. The white
marked numbers refer to alginate; the grey marked numbers refer to standard
antigen.
⁎ :Pb0.05, ¤:Pb0.01 and ‡:Pb0.0001 and when the CF+P(i) are compared
with CF-P or when the CF+P(i) are compared with CF+P(c). None of the
values form the control group differed signiﬁcantly from the CF-P group.
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IgA in nasal secretion/serum (Table 1) and in saliva/serum
(Table 2) compared with CF-P.
ROC-curves were used for finding the best cut-off values
between CF+P(i) and CF-P:
Nasal IgA: A cut-off value of 1.09 for nasal IgA-St-Ag gave
76% sensitivity and 87% specificity. A cut-off value of 0.54 for
nasal IgA-alginate gave 75% sensitivity and 94% specificity.
When these cut-off values of the two nasal IgA tests (IgA-alginate
and IgA-St-Ag) were combined, CF+P(i) could be discriminated
from CF-P with 96%, sensitivity, 81% specificity, 79% predictiveFig. 2. A Box-and-whisker plot of the IgA values (OD) against alginate in nasal
secretions distributed on four infection categories, showing the 2½, 25, 50, 75
and 97½% percentiles. CF+P(c), CF+P(i) and CF-P all differed significantly
(Pb0.0001) from each other.value of a positive test (pvpos), and 96% predictive value of a
negative test (pvneg) .
Saliva IgA: A cut-off value of 0.27 for saliva IgA-St-Ag gave
64% sensitivity of and 74% specificity. A cut-off value of 0.24 for
saliva IgA-alginate gave 55% sensitivity and 74% specificity.
When the cut-off values of the two saliva IgA tests were combined,
CF+P(i) could be discriminated from CF-P with 72%, sensitivity,
74%, specificity, 87% pvpos, and 52% pvneg .
Nine sputum samples and 17 nasal secretions were obtained
from CF-P. In general, the antibody levels were higher in CF-P
than in CF-GNB but lower than in CF+P(c).
There was a significant correlation between IgA-alginate in
nasal secretions and saliva (rho=0.60) and between IgA-St-Ag
in nasal secretions and saliva (rho=0.51) from the seventy-five
CF patients where these values were available (P-valuesb0.0001).
In eighteen of 20 CF-P patients (90%), sputum samples with
S. aureus, H. influenzae, S. pneumoniae or Aspergillus spp.
were cultured. There was agreement in 12/20 (60%) of the nasal
irrigation cultures and in 9/20 (45%) of the nasal swabs from
the middle meatus cultures when compared with the sputum
bacteriology. In one CF-P patient, S. malthophilia were found
in sputum and nasal irrigation but these bacteria were not found
by culture from the middle meatus swabs.
By immunohistochemistry examinations we found excessive
amounts of IgA producing plasma cells in the sino-nasal tissue.
They were mostly found in the connective tissue of the lamina
propria (Fig. 1C), with higher concentration in focal areas close
to the mucosal surface (Fig. 1D). Accumulations of the IgA
producing cells were also seen around the secretory acini
(Fig. 1E). IgA was also detected in the layer of mucus on the
luminal mucosal surface (Fig. 1D) and in the secretions in the
excretory ducts from the submucosal glands (Fig. 1F).
4. Discussion
We have previously reported that CF+P(c), in contrast to
healthy persons, had high levels of IgA against P. aeruginosa
alginate and St-Ag in sputum, saliva and tears and that the IgA
contained a secretory component (sIgA) [4]. The high ratio of IgA
in saliva, tears, and sputum versus serum also showed a local IgA
production in contrast to the low ratio of IgG in the secretions
versus serum in accordance with the systemic production of this
immunoglobulin class [4]. The specific IgA response to P.
aeruginosa in these secretions reflects the common mucosal
immune response to offending microbes. Since our previous report
(4;), P. aeruginosa sinusitis has attracted increasing attention as a
focus for subsequent lung colonization and chronic infection
[6,9,11–14,20,22]. Thus, we have expanded the study [4] in order
to evaluate whether sIgA against P. aeruginosa can contribute to
the diagnosis of P. aeruginosa sinusitis before onset of the chronic
lung infection. In another article, more details are given about the
bacteriological and clinical results from functional endoscopic
sinus surgery on a large number of CF patients with sinusitis [6].
In the present study we also investigate IgA against P.
aeruginosa alginate and St-Ag in saliva and serum, but in
contrast to our earlier study [4] we now include nasal secretions
and a greater number of CF patients, now subdivided according
86 K. Aanaes et al. / Journal of Cystic Fibrosis 12 (2013) 81–87to the lung infection status. Significant differences of IgA levels
to the P. aeruginosa antigens were seen between both
CF+P(c), CF+P(i) and CF-P. Accordingly, we also found an
abundance of local IgA producing plasma cells in the nasal
mucosa of CF+P(c) CF+P(i). Many plasma cells have
previously been found in sinonasal tissue from CF patients
[23]. Importantly, our results allow a differentiation between
CF+P(i) and CF-P. Nevertheless, the test is limited by the
possibility of cross-reaction with other pathogenic Gram-
negative bacteria (e.g. S. malthophilia, A. xylosoxidans or
B. cepacia complex) [15]. We conclude that the sensitivity,
specificity, pvpos, and pvneg of each of the results of the IgA
ELISAs or combined ELISA results are high enough to be
evaluated as a diagnostic tool for P. aeruginosa sinusitis in a
prospective study in our CF centre.
IgA concentration is in general elevated as a result of the
local mucosal antibody response, whereas IgG is elevated as a
consequence of the systemic inflammatory response [4,7]. Our
results indicate an early, local production of IgA in the sinuses
when these are infected with P. aeruginosa. This assumption is
fortified, as we did not find P.aeruginosa in the nasal irrigation
or middle meatus cultures from CF-P, which indicates that the
sinuses are also free from P.aeruginosa [22,24]. This result can
be compared with our previous findings of pathogenic bacteria
in the majority of the sinuses in CF+P(i) and CF+P(c) [6].
Our results are therefore in accordance with our previous
findings of high IgA levels in saliva, tears and sputum [4] and
additionally show that nasal secretions contain even higher levels.
This is in agreement with the increasing evidence of P. aeruginosa
sinusitis being a focus for subsequently intermittent lung
colonization and infection [6,9,11–14,22]. When P. aeruginosa
settles in the paranasal sinuses, a local increase of mucosal IgA
response is initiated. However, the inflammatory response is
reduced compared with that of chronic lung infection since the
secretory IgA is non-phlogistic in contrast to IgG which forms
immune complexes with P. aeruginosa antigens and activate
complement and attract PMNs in the respiratory zone of the lungs
[1,6,10]. The result may be that IgA keeps P. aeruginosa at a
distance from the cells of mucosal membranes [25] and thereby
diminishing the clinical symptoms of sinusitis [10]. The same
mechanism may be working in the conductive airways of
CF+P(c), where most P. aeruginosa are located inside sputum
together with the highly active PMNs [1,26,27], probably also due
to IgA in mucosa and mucus in the conductive airways [4].
Keeping the bacteria at a distance from the mucosal membrane
cells may be a common strategy in the respiratory and intestinal
tracts [25] by means of the mucus layer and the anti-bacterial
molecules such as IgA which prevent inflammation. P. aeruginosa
sinusitis in CF may therefore resemble secretory otitis media with
effusion where bacterial biofilms and IgA have also been found
[28–30].
There are no standardized guidelines for detection of upper
airway P. aeruginosa colonization or how or when to eradicate
CF-pathogenic bacteria from the CF sinuses by sinus surgery and/
or with antibiotic treatment [24,31]. The potential of surgical and/
or conservative antibiotic treatment for eradication of P.aeruginosa
sinusitis requires further prospective evaluation; for now an earlystage attempt of eradicating P. aeruginosa may be considered
when detected in the sinus [6,9,11,12,22,32].
A prospective study is planned to examine if the IgA response
in nasal secretion or saliva is helpful for early diagnosis of
P.aeruginosa sinusitis. It would also be relevant to investigate
whether IgA in nasal secretions, collected through a gentle nasal
lavage, is an easier way to collect IgA or if the method is
complicated by dilution problems. Nasal lavage is already used as
a supplementary diagnostic tool for CF infections [22], and as a
research tool for rhinitis [33].
5. Conclusions
Both CF+P(c) and CF+P(i) have significantly higher IgA
antibody levels in nasal secretions and saliva against P.
aeruginosa alginate and St-Ag compared to CF-P. In CF+P(i)
the elevated IgA probably reflect P. aeruginosa sinusitis where
the bacteria adapt to the environment of CF airways CF
patients; sinusitis may then be the focus for subsequent
intermittent P. aeruginosa colonization and chronic infection
of the lungs. The diagnostic value of IgA in saliva and nasal
secretions for sinusitis will be studied prospectively.
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